- Home
- GVH vs LSB Comparison
GVH vs LSB Comparison
Compare GVH & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- LSB
- Stock Information
- Founded
- GVH 2016
- LSB 2002
- Country
- GVH Australia
- LSB China
- Employees
- GVH N/A
- LSB N/A
- Industry
- GVH
- LSB
- Sector
- GVH
- LSB
- Exchange
- GVH Nasdaq
- LSB NYSE
- Market Cap
- GVH 22.8M
- LSB 22.3M
- IPO Year
- GVH 2023
- LSB N/A
- Fundamental
- Price
- GVH $1.37
- LSB $1.00
- Analyst Decision
- GVH
- LSB
- Analyst Count
- GVH 0
- LSB 0
- Target Price
- GVH N/A
- LSB N/A
- AVG Volume (30 Days)
- GVH 99.9K
- LSB 14.1K
- Earning Date
- GVH 02-12-2025
- LSB 06-21-2025
- Dividend Yield
- GVH N/A
- LSB N/A
- EPS Growth
- GVH 12.04
- LSB N/A
- EPS
- GVH 0.09
- LSB N/A
- Revenue
- GVH $16,540,178.00
- LSB $79,415,311.00
- Revenue This Year
- GVH N/A
- LSB $39.33
- Revenue Next Year
- GVH N/A
- LSB $75.61
- P/E Ratio
- GVH $14.79
- LSB N/A
- Revenue Growth
- GVH N/A
- LSB N/A
- 52 Week Low
- GVH $0.47
- LSB $0.36
- 52 Week High
- GVH $1.82
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- GVH 57.93
- LSB 30.24
- Support Level
- GVH $1.33
- LSB $0.91
- Resistance Level
- GVH $1.45
- LSB $1.09
- Average True Range (ATR)
- GVH 0.15
- LSB 0.06
- MACD
- GVH -0.05
- LSB 0.02
- Stochastic Oscillator
- GVH 11.76
- LSB 29.03
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.